The RPD designation is a positive regulatory catalyst that adds potential PRV value to ALXN1840, but the stock's reaction will depend on the market's view of the probability of NDA submission and approval. Monitor for NDA filing timing and any partnership or PRV sale announcements.
Price Chart
Executive Summary
Monopar Therapeutics announced that the FDA granted Rare Pediatric Disease (RPD) designation to ALXN1840 (tiomolibdate choline) for the treatment of Wilson disease. This designation makes the company eligible to receive a pediatric Priority Review Voucher (PRV) upon potential future NDA approval, which can be sold or transferred. The news is a positive regulatory milestone but does not change the fundamental risk profile of the still-clinical-stage pipeline.
Key Facts
- FDA granted Rare Pediatric Disease (RPD) designation to ALXN1840 (tiomolibdate choline) for Wilson disease.
- RPD designation makes Monopar eligible for a pediatric Priority Review Voucher (PRV) upon potential NDA approval.
- PRVs can be sold or transferred to another sponsor and have historically transacted for significant value.
- ALXN1840 met its primary endpoint in a Phase 3 pivotal trial, demonstrating rapid and sustained copper mobilization vs. standard of care over 48 weeks.
- Safety and tolerability data were observed across 645 patient-years of follow-up in 266 patients.
- ALXN1840 is an oral tablet with once-a-day dosing.
Financial Impact
No financial figures provided in the filing. PRVs have historically sold for $67M to $350M, but no value is stated here.
Risk Factors
- ALXN1840 has not yet received marketing approval; NDA submission and FDA review remain uncertain.
- The PRV program could be modified or discontinued by the FDA or Congress.
- Monopar is a clinical-stage company with no approved products and may need additional capital to fund development and commercialization.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-022086 |
| Exhibit: ex_982910.htm | 0001437749-26-022086 |
| Document: 0001437749-26-022086-index-headers.html | 0001437749-26-022086 |
| Document: 0001437749-26-022086-index.html | 0001437749-26-022086 |
| Document: 0001437749-26-022086.txt | 0001437749-26-022086 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | Insider Cluster | $79.57 | awaiting T+60 | — | $70.54 (+11.35%) |
Oct 1, 2026 25d ago | 144 | $77.97 | awaiting T+60 | — | $70.54 (−9.53%) |
Aug 28, 2026 8w ago | Insider Cluster | $111.93 | awaiting T+60 | — | $70.54 (−36.98%) |
Aug 27, 2026 8w ago | Insider Cluster | $111.89 | awaiting T+60 | — | $70.54 (−36.96%) |
Aug 25, 2026 8w ago | 144 | $113.72 | awaiting T+60 | — | $70.54 (−37.97%) |
Aug 12, 2026 10w ago | 8-K | $114.90 | awaiting T+60 | — | $70.54 (−38.61%) |
Aug 12, 2026 10w ago | Press Release | $114.90 | awaiting T+60 | — | $70.54 (−38.61%) |
Jul 22, 2026 13w ago | 8-K | $112.48 $71.80 | ▼ −36.17% | ▼ −39.43% | $70.54 (−37.29%) |
Jul 22, 2026 13w ago | Press Release | $112.48 $71.80 | ▼ −36.17% | ▼ −39.43% | $70.54 (−37.29%) |
Jun 30, 2026 16w ago | 8-K | $92.59 $89.38 | ▼ −3.47% | ▼ −7.03% | $70.54 (−23.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers